Skip to main content
OpenTrials

Clinical trial condition

Refractory Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type

Explore clinical trials studying Refractory Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type. Study availability and eligibility vary by location and protocol.

4 public trials 3 recruiting studies
Refine in advanced search Browse all conditions

Refractory Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type trial results

Recruiting

Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma

NCT06649812

Conditions
Hemic and Lymphatic Diseases, High Grade B-Cell Lymphoma With MYC and BCL6 Rearrangements, Immune System Diseases, +23 more
Locations
  • Banner University Medical Center - Tucson Tucson, Arizona, United States
  • University of Arizona Cancer Center-North Campus Tucson, Arizona, United States
  • Cedars-Sinai Medical Center Los Angeles, California, United States
  • Smilow Cancer Hospital-Derby Care Center Derby, Connecticut, United States
View all 86 locations
View Trial Details
Recruiting

Golcadomide and Rituximab as Bridging Therapy for Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma Before CAR T-cell Therapy

NCT06834373

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +39 more
Locations
  • Mayo Clinic in Arizona Scottsdale, Arizona, United States
  • Mayo Clinic in Florida Jacksonville, Florida, United States
  • Mayo Clinic Health System in Albert Lea Albert Lea, Minnesota, United States
  • Mayo Clinic Health Systems-Mankato Mankato, Minnesota, United States
View Trial Details
Active, Not Recruiting

Testing the Safety of the Anti-cancer Drugs Tazemetostat and Belinostat in Patients With Lymphomas That Have Resisted Treatment

NCT05627245

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +24 more
Locations
  • University of California Davis Comprehensive Cancer Center Sacramento, California, United States
  • Yale University New Haven, Connecticut, United States
  • University of Kansas Clinical Research Center Fairway, Kansas, United States
  • University of Kansas Cancer Center Kansas City, Kansas, United States
View Trial Details

Related conditions